This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, Z. Articles by Halmos, B. Search for Related Content PubMed PubMed Citation Articles by Yu, Z. Articles by Halmos, B.

Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies

¹ Divisions of Hematology/Oncology and ² Pulmonary, Critical Care and Sleep Medicine, Case Western Reserve University, Cleveland, Ohio; ³ Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut; ⁴ Beth Israel Deaconess Medical Center, Harvard Medical School; ⁵ Harvard Institutes of Medicine, Boston, Massachusetts; and ⁶ Harbin Medical University, Heilongjiang, China

Requests for reprints: Balazs Halmos, Ireland Cancer Center, Case Western Reserve University, Cleveland, OH-44106-7284. Phone: 216-368-3362; Fax: 216-368-1166; E-mail: bxh60{at}case.edu.

Patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, limiting their long-term efficacy. Irreversible EGFR inhibitors such as CL-387,785 can overcome resistance and are in clinical development, yet acquired resistance against these agents is anticipated. We carried out a cell-based, in vitro random mutagenesis screen to identify EGFR mutations that confer resistance to CL-387,785 using T790M-mutant H1975 lung adenocarcinoma cells. Mutations at several residues occurred repeatedly leading to functional resistance to CL-387,785. These variants showed uninhibited cell growth, reduced apoptosis, and persistent EGFR activation in the presence of CL-387,785 as compared with parental H1975 cells, thus confirming their role in resistance. A screen of alternative agents showed that both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant inhibition of cell growth of the resistant mutants, suggestive of potential alternative treatment strategies. These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non–small cell lung cancers. [Cancer Res 2007;67(21):10417–27]

This article has been cited by other articles:

				S. A. Milligan, P. Burke, D. T. Coleman, R. L. Bigelow, J. J. Steffan, J. L. Carroll, B. J. Williams, and J. A. Cardelli The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer Cells Clin. Cancer Res., August 1, 2009; 15(15): 4885 - 4894. [Abstract] [Full Text] [PDF]

				J. Bean, G. J. Riely, M. Balak, J. L. Marks, M. Ladanyi, V. A. Miller, and W. Pao Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma Clin. Cancer Res., November 15, 2008; 14(22): 7519 - 7525. [Abstract] [Full Text] [PDF]

				H. M. Schuller, H. A.N. Al-Wadei, and M. Majidi Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma Carcinogenesis, October 1, 2008; 29(10): 1979 - 1985. [Abstract] [Full Text] [PDF]

				A. Kumar, E. T. Petri, B. Halmos, and T. J. Boggon Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1742 - 1751. [Abstract] [Full Text] [PDF]

				N. Godin-Heymann, L. Ulkus, B. W. Brannigan, U. McDermott, J. Lamb, S. Maheswaran, J. Settleman, and D. A. Haber The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor Mol. Cancer Ther., April 1, 2008; 7(4): 874 - 879. [Abstract] [Full Text] [PDF]